The Estrogenic Effect of Bisphenol A Disrupts Pancreatic β-Cell Function In Vivo and Induces Insulin Resistance by Alonso-Magdalena, Paloma et al.
106 VOLUME 114 | NUMBER 1 | January 2006 • Environmental Health Perspectives
Research
Insulin resistance is a crucial constituent of the
metabolic syndrome, and its presence predicts
type 2 diabetes and atherosclerotic cardio-
vascular disease (DeFronzo and Ferrannini
1991). In addition to insulin resistance, type 2
diabetes mellitus is also characterized by a pro-
gressive β-cell dysfunction. In most patients,
both symptoms are present several years
before the onset of hyperglycemia.
The incidence of diabetes has increased in
the last decades, and at present it is reaching
epidemic levels (177 million persons with dia-
betes in the world; World Health Organization
2005). The cornerstones of its development
are related to modern lifestyle, principally, a
lack of exercise and an unhealthy diet. Other
pathologies whose incidence rose dramatically
after World War II, such as cancer, reproduc-
tive impairment, and neurodegenerative dis-
eases, are probably related to the increase of
endocrine-disrupting chemicals (EDCs) in the
environment (Colborn et al. 1996). However,
an experimental link between EDCs and dia-
betes has not yet been established, although a
connection at the epidemiologic level in
humans has been recently proposed for
dioxin, an environmental contaminant that
acts through other than estrogen receptors
(ERs) as an endocrine disruptor (Bertazzi et al.
2001; Rene and Bunce 2002).
A large number of EDCs act by mimicking
the action of the sex hormone 17β-estradiol
(E2) (Colborn et al. 1993). In most cases they
bind to the classic ERs, ER-α and ER-β
(McLachlan 2001; Newbold 2004), but they
can also act through novel estrogen targets
(Nadal et al. 2005). At physiologic levels, E2 is
thought to be involved in maintaining normal
insulin sensitivity and to be beneﬁcial for β-cell
function (Livingstone and Collison 2002;
Louet et al. 2004). However, abnormal levels
of E2 may promote insulin resistance
(Livingstone and Collison 2002), similar to
what occurs in normal puberty and pregnancy
(Amiel et al. 1991; Hollingsworth 1983).
Therefore, the exposure to an exogenous
chemical acting as the natural hormone E2, but
at an inappropriate concentration and during
an improper time window, may enhance the
risk of developing insulin resistance.
In spite of the many clinical studies that
link sex steroids and actions of insulin, few
studies have investigated the molecular basis
of the interaction between E2, the pancreatic
β-cell function, blood glucose homeostasis,
and the development of diabetes. Pancreatic
β-cells contain both types of ERs, ER-α and
ER-β (Nadal et al. 2000). Although their
functions are still greatly undetermined, ER-α
and ER-β are involved in important aspects of
the β-cell physiology (Nadal et al. 2004;
Sutter-Dub 2002). These include protection
against β-cell death caused by cytokines
(Contreras et al. 2002) and, after a prolonged
application, a beneﬁcial effect on diabetes in
mice expressing human islet amyloid peptide
(Geisler et al. 2002). The involvement of ERs
in lipid and glucose metabolism has been
demonstrated in ER-α knockout mice that
display increased adiposity, insulin resistance,
and glucose intolerance (Heine et al. 2000).
In addition, β-cells have the nonclassical
membrane ER (ncmER) that triggers rapid
effects (Nadal et al. 1998, 2000; Quesada
et al. 2002). Recently, a similar receptor has
been found in Drosophila (Srivastava et al.
2005). E2 rapidly potentiates β-cell signaling
systems and insulin release via this ncmER, an
effect that is mimicked by EDCs, including
bisphenol A (BPA) (Nadal et al. 2004). BPA is
one of the most common chemicals that
behaves as an endocrine disruptor. It was the
ﬁrst synthetic estrogen without a steroid struc-
ture (Dodds and Lawson 1936), but because
of its properties as a cross-linking chemical,
BPA was widely chosen by the chemical indus-
try to produce plastic polymers, mainly poly-
carbonates. Nowadays, it is used in the
manufacture of barrier coatings for the inner
surfaces of food and beverage cans. High con-
centrations of BPA have been detected in food
and water extracted from autoclaved cans
(Brotons et al. 1995). BPA is one of the high-
est-volume chemicals produced in the world,
and its exposure is widespread: it has been
found in 95% of the urine samples from peo-
ple in the United States and to a similar extent
is found in human blood, as well (Ikezuki et al.
2002; vom Saal and Hughes 2005). The
European Commission’s Scientiﬁc Committee
on Food (ECSCF 2002) reported a tolerable
daily intake (TDI) of 10 µg/kg/day. However,
the U.S. Environmental Protection Agency
(U.S. EPA) considers 50 µg/kg/day the refer-
ence dose based on the lowest observed adverse
effect level (LOAEL) of 50 mg/kg/day, accord-
ing to studies performed in the 1980s (vom
Saal and Hughes 2005). In vivo studies using
much lower doses of BPA than the LOAEL
have shown that it affects sexual maturation
(Howdeshell et al. 1999), induces a decrease in
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The function of the pancreatic β-cell is the storage and release of insulin, the main hormone
involved in blood glucose homeostasis. The results in this article show that the widespread
environmental contaminant bisphenol-A (BPA) imitates 17β-estradiol (E2) effects in vivo on
blood glucose homeostasis through genomic and nongenomic pathways. The exposure of adult
mice to a single low dose (10 µg/kg) of either E2 or BPA induces a rapid decrease in glycemia
that correlates with a rise of plasma insulin. Longer exposures to E2 and BPA induce an increase
in pancreatic β-cell insulin content in an estrogen-receptor–dependent manner. This effect is vis-
ible after 2 days of treatment and starting at doses as low as 10 µg/kg/day. After 4 days of treat-
ment with either E2 or BPA, these mice developed chronic hyperinsulinemia, and their glucose
and insulin tolerance tests were altered. These experiments unveil the link between environmen-
tal estrogens and insulin resistance. Therefore, either abnormal levels of endogenous estrogens or
environmental estrogen exposure enhances the risk of developing type 2 diabetes mellitus, hyper-
tension, and dyslipidemia. Key words: bisphenol A, diabetes, endocrine disruptors, estradiol,
estrogen receptor, insulin, islet of Langerhans, nongenomic, xenoestrogens. Environ Health
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20 September 2005]daily sperm count and fertility (vom Saal et al.
1998), disrupts chromosome alignment (Hunt
et al. 2003), and affects synaptogenesis
(McLusky et al. 2005). In spite of this evi-
dence, there is an ongoing debate with the
chemical industry that is still skeptical about
the risk of low doses of BPA (Bisphenol A
Global Industry Group 2005). 
In this article we show that the exposure
of adult mice to BPA, at doses about
1,000-fold less than the LOAEL established
by the U.S. EPA, alters blood glucose home-
ostasis in vivo. It rapidly increases plasma
insulin, altering blood glucose concentration
through a nonclassical estrogen pathway.
Longer exposure increases β-cell insulin con-
tent, an effect that involves classic ERs. These
longer exposures generate chronic hyperinsu-
linemia in the fed state and peripheral insulin
resistance.
Materials and Methods
Materials. We obtained ICI182,780 (ICI)
from Tocris Cookson Ltd. (Avonmouth,
UK), tocopherol-stripped corn oil from MP
Biomedicals, LLC (Solon, OH, USA), and
soluble insulin from Humulina Regular
(Lilly, Madrid, Spain). Other substances were
obtained from Sigma (Madrid, Spain).
Animals. We used Swiss albino OF1 male
mice (8–10 weeks of age) throughout this
study. All animals were kept under standard
housing conditions and were treated humanely
and with regard for alleviation of suffering. An
internal animal care and use committee
reviewed and approved the method used.
Treatment. Stimuli (E2 and BPA) were
dissolved in tocopherol-stripped corn oil and
administered subcutaneously at various con-
centrations. The amount of vehicle was kept
constant at 100 µL. In long-term experi-
ments, animals were injected twice per day, at
0900 hr and 2000 hr, with 50 µg/kg or
5 µg/kg of test compound. Two injections of
50 µg/kg/day during 4 days gave a plasma
concentration of E2 similar to that found in
late pregnancy (Song et al. 2001). In ICI
experiments, animals were injected intraperi-
toneally with a single dose of 500 µg/kg/day
for 3–4 days, always at 0800 hr.
Glycemia determination. We determined
glucose in blood obtained from the tail vein
using an Accu-check compact glucometer
(Roche Diagnostic GmbH, Mannheim,
Germany).
Insulin secretion and content. To measure
plasma insulin, mice were anesthetized with
50 mg/kg body weight sodium pentobarbital.
Blood (~ 1 mL) was obtained by cardiac
puncture with a syringe containing 24 mM
EDTA. We determined the levels of plasma
insulin by enzyme-linked immunosorbent
assay (ELISA) using a mouse insulin assay kit
from Mercodia AB (Uppsala, Sweden).
To measure insulin release from isolated
islets, mice were killed by cervical dislocation,
and pancreatic islets of Langerhans were iso-
lated by collagenase digestion as described
previously (Morimoto et al. 2001). Islets were
washed twice with a buffer solution contain-
ing 20 mM HEPES, 115 mM NaCl, 5 mM
NaHCO3, 5 mM KCl, 2.6 mM CaCl2,
1.2 mM KH2PO4, 1.2 mM MgSO4, 3 mM
D-glucose, and 1% bovine serum albumin
(pH 7.4). Groups of 10 islets were then incu-
bated in 1 mL of this buffer in the presence of
3, 7, and 16 mM glucose. After 1 hr, the
medium was collected, and insulin was meas-
ured in duplicate samples by radioimmuno-
assay using a Coat-a-Count kit (DPC, Los
Angeles, CA, USA).
The insulin content was determined in
islets isolated as described above. Islets were
grouped in batches of 10 and incubated
overnight in an ethanol/HCl buffer at 4°C. At
the end of the incubation period, the buffer
was removed and studied for insulin content
using radioimmunoassay with a Coat-a-Count
kit (DPC). Protein determination was per-
formed by the Bradford dye method.
Immunocytochemistry and insulin content.
Islets isolated as above were dispersed into sin-
gle cells as previously described (Nadal et al.
1998). Briefly, islets were disaggregated into
single cells with trypsin. Cells were then cen-
trifuged and resuspended in Hank’s modiﬁed
medium supplemented with 200 U/mL peni-
cillin, 0.2 mg/mL streptomycin, 5 mM glu-
cose, and 1% fatty acid–free albumin, pH 7.4.
They were then plated on 24-well tissue cul-
ture plates. After 30 min, cells were washed
with phosphate-buffered saline (PBS) and ﬁxed
with Bouin’s solution for 5 min. Then, they
were dehydrated with 30, 50, and 70%
ethanol, 3 min each, and then washed with
PBS. After washing, these cells were ﬁrst incu-
bated with a monoclonal anti-insulin antibody
(1:200 dilution; Sigma, Madrid, Spain) for
2 hr and then for 1 hr with a secondary anti-
body, anti-mouse IgG-conjugated ﬂuorescein
isothiocyanate (IgG-FITC; 1:200 dilution;
Sigma), both at room temperature. Cells were
washed with PBS overnight. Images were
acquired with a confocal microscope Zeiss
Pascal 5 using a Zeiss 20× objective (numerical
aperture = 0.5) and analyzed using LSM Zeiss
software (Zeiss, Jena, Germany). We measured
immunofluorescence intensity in random
fields. The results were expressed as average
pixel intensity and normalized with respect to
vehicle-treated animals. Pixel intensity was nor-
malized with respect to the mean value of the
pixel intensity of vehicle-treated animals at the
corresponding days.
Glucose and insulin tolerance tests. For
glucose tolerance tests, animals were fasted
overnight for 12 hr, and blood samples were
obtained from the tail vein. Animals were then
injected intraperitoneally with 2 g/kg body
weight of glucose, and blood samples were
taken at the indicated intervals.
For insulin tolerance tests, fed animals
were used. Animals were injected intra-
peritoneally with 0.75 IU/kg body weight of
soluble insulin. Blood glucose was measured
in each sample using an Accu-check compact
glucometer (Roche). 
Statistical analysis. Data are expressed as
mean ± SE. Pairwise comparisons were made
using Student’s t-test. A probability level
< 0.05 was considered statistically signiﬁcant.
Results
E2 and BPA rapidly alter glycemia and insu-
linemia. In vitro, both E2 and BPA alter the
function of pancreatic β-cells through the
ncmER (Nadal et al. 1998, 2000; Quesada
et al. 2002; Ropero et al. 2002). In vivo, the
administration of 10 µg/kg E2 to adult male
mice resulted in a significant decrease of
glycemia measured at 30, 60, and 120 min
after the injection, compared to the increase
of blood glucose produced by the fatty acids
contained in the vehicle injection (toco-
pherol-stripped corn oil) (Figure 1A). The
administration of 1, 10, and 100 µg/kg E2
evoked a clear dose-dependent decrease in the
rise of glycemia 30 min after the E2 injection
(Figure 1B). This effect is mimicked by equal
doses of the environmental estrogen BPA
(Figure 1C). Thirty minutes after injection,
this decrease in blood glucose is parallel to an
increase in plasma insulin (Figure 1D) of 3.20
± 0.45-fold for E2-treated mice and 2.76 ±
0.5-fold for BPA-treated mice. Rapid effects
elicited by E2 and BPA in islets of Langerhans
in vitro are initiated after they bind at the
ncmER that is insensitive to the pure anti-
estrogen ICI (Nadal et al. 2004). This anti-
estrogen was described as blocking classic
ER-mediated actions in vivo (Johnson et al.
2003; Perez-Martin et al. 2003). To evaluate
whether the E2 and BPA actions described
above require an ER with a sensitivity to the
pure antiestrogen similar to a classical ER, we
undertook experiments using mice treated
with 500 µg/kg/day ICI administered
intraperitoneally for 3 days (Johnson et al.
2003). As shown in Figure 2A, ICI had no
effect on the E2 and BPA-dependent blood
glucose decrease nor on the E2- and BPA-
dependent increase of plasma insulin
(Figure 2B).
Therefore, both E2 and BPA rapidly
change glycemia most likely by inducing an
hypersecretion of insulin through a non-
classical ER-mediated mechanism that may
involve the ncmER previously described in
these cells (Nadal et al. 2000, 2004).
E2 and BPA increase β-cell insulin con-
tent. Adult male mice were injected twice a
day with the vehicle, E2 or BPA for 4 days.
Bisphenol A induces insulin resistance
Environmental Health Perspectives • VOLUME 114 | NUMBER 1 | January 2006 107Afterward, insulin content was measured in
individual cells by immunocytochemistry.
Figure 3A shows confocal images of β-cells
obtained from mice treated 4 days with vehi-
cle, 100 µg/kg/day E2, or 100 µg/kg/day BPA.
Figure 3B illustrates a three-dimensional
reconstruction of images in Figure 3A showing
a pixel intensity scale from 0 to 256 pixels.
The images and the three-dimensional graphs
illustrate that β-cells from animals treated with
E2 and BPA presented higher staining than
those treated with the vehicle and thus higher
insulin content in every cell. After 4 days of
treatment, the insulin increase was already
manifested at doses of 10 µg/kg/day of either
E2 or BPA (Figure 3C). Nonetheless, this
effect was small and 100 µg/kg/day was
needed to produce a potent increase in
insulin content (Figure 3C). A treatment of
100 µg/kg/day E2 for 4 days gives an E2
plasma concentration similar to that found in
late pregnancy (Song et al. 2001). Therefore,
the chronic action of E2 and BPA was mani-
fested at higher concentrations than was
required for the acute effect. On the basis of
this response, we use 100 µg/kg/day as the
paradigmatic concentration in long-term
experiments. 
Time-course experiments demonstrated
that the onset of the increase in insulin content
occurs after 24–48 hr of treatment with either
E2 or BPA (Figure 3D). The experiment in
Figure 3D shows that most single β-cells
increased their insulin content. The experiment
in Figure 3D shows that after 4 days of treat-
ment, the insulin content is higher in E2 and
BPA-treated mice. The radioimmunoassay
analysis of insulin content performed 4 days
after the treatment with 100 µg/kg/day of
either E2 or BPA produced similar results as
those presented with immunocytochemistry
(Figure 3E). These results demonstrate that the
insulin content was increased by both the nat-
ural hormone and the environmental estrogen
to a similar extent.
To study the involvement of classical ERs
in the regulation of E2- and BPA-induced
insulin expression, we used mice treated with
the antiestrogen ICI, as described for the
experiment presented in Figure 2. Animals
treated with 100 µg/kg/day E2 for 4 days pre-
sented higher levels of insulin immuno-
reactivity than the control (Figure 4A). In
animals treated with ICI, E2 had no effect
(Figure 4A). The action of the pure anti-
estrogen is manifested to the same extent with
BPA, as demonstrated by immunocyto-
chemistry (Figure 4B) and radioimmunoassay
(Figure 4C). The ability of the pure anti-
estrogen to completely block the effect of
both E2 and BPA indicates that the action
performed on insulin content is mediated by
a classical ER.
E2 and BPA administration provokes
hyperinsulinemia and insulin resistance. An
increment in the insulin content of every β-cell
within an islet causes it to release a higher
amount of insulin every time it is stimulated
(Marban et al. 1989). This occurs, for instance,
during pregnancy, when islets adapt to deal
with peripheral insulin resistance (Costrini and
Kalkhoff 1971; Faure et al. 1985). In our sys-
tem (Figure 5A), we show that, at high glucose
concentrations (16 mM), islets from mice
treated with 100 µg/kg/day E2 for 4 days
secrete 1.54 ± 0.12-fold more insulin than
those from mice treated with the vehicle, and
the same occurs in islets from mice treated
Alonso-Magdalena et al.
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Figure 2. Increment of glycemia (A) and plasma insulin (B) 30 min after the injection of vehicle, 10 µg/kg E2,
or 10 µg/kg BPA in animals with or without treatment with ICI (500 µg/kg/day) for 3 days. 
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Figure 1. Rapid change in blood glucose levels with E2 and BPA compared with tocopherol-free corn oil
(vehicle). (A) Measurement of blood glucose concentration in animals fasted for 12 hr, injected with 100 µL
vehicle or 10 µg/kg body weight E2 (n = 6–14 mice); *p < 0.05. (B) Increment of glycemia 30 min after the
injection of vehicle or E2 (n = 7–16); *p < 0.05 compared with vehicle. (C) Increment of glycemia 30 min
after the injection of vehicle or BPA (n = 4–10); *p < 0.05 compared with vehicle. (D) Circulating plasma
insulin in fasted (12 hr) animals 30 min after the injection of vehicle, 10 µg/kg E2 or 10 µg/kg BPA (n = 8–16);
*p = 0.024, and **p = 0.004 compared with vehicle. Error bars indicate SE. with BPA. In the latter case, differences are sig-
niﬁcant even at lower glucose concentrations
(7 mM). This effect has been recently
described in vitro (Adachi et al. 2005).
Therefore, if E2- and BPA-treated mice have
higher insulin content, they should release
more insulin than untreated mice, and
accordingly, these animals should be hyper-
insulinemic in the fed state. This is shown in
Figure 5B: 4 days after the E2 treatment, fed
mice had blood insulin levels 1.7-fold higher
than those of vehicle-treated mice. Blood glu-
cose levels were 186 ± 5 mg/dL in vehicle-
treated mice and 170 ± 6 mg/dL in E2-treated
mice (p = 0.065, not significant). Plasma
insulin levels for the group treated with BPA
were 1.5-fold higher than those for the vehi-
cle-treated mice; however, their blood glucose
levels were 153 ± 4 mg/dL for the vehicle (n =
5) and 154 ± 7 mg/dL for BPA (n = 7; p =
0.93). This experiment indicates that, in the
E2-treated animals, there was mild insulin
resistance, because there are 1.7-fold higher
circulating insulin levels but a decrease of
blood glucose, although it is not significant.
This effect is remarkably manifested with
BPA; in this case, plasma insulin levels are
1.53-fold higher and blood glucose concen-
tration does not vary, a clear symptom of
insulin resistance.
To prove that glucose tolerance is altered,
we performed an intraperitoneal glucose tol-
erance test in fasted (12 hr) mice. Contrary to
vehicle-treated mice, blood glucose increased
to a higher level in E2-treated (Figure 6A) and
BPA-treated mice (Figure 6B). The higher
increase in blood glucose manifested 15 and
30 min after a glucose challenge. We found
that the area under the curve (milligrams per
deciliter-minute) was 162 ± 6 (vehicle, n =
24), 181 ± 5 (E2, n = 16, p = 0.025 vs. vehi-
cle), and 190 ± 8 (BPA, n = 8, p = 0.028 vs.
vehicle). These results indicate that an
impaired glucose tolerance was present in E2-
treated mice and in those treated with BPA.
When an insulin tolerance test (intraperi-
toneal injection of 0.75 IU/kg body weight
soluble insulin) was performed in fed mice, a
significantly reduced hypoglycemic response
was observed in both E2- and BPA-treated
mice (Figure 6C). This insulin intolerance
also manifested in animals given an oral dose
of 100 µg/kg/day BPA for 4 days. In this case,
the BPA was dissolved in tocopherol-stripped
corn oil and delivered through a pipette
placed into the animal’s mouth (Howdeshell
et al. 1999) (Figure 6D). All these results
indicate that E2-treated animals and, in a
remarkably similar manner, BPA-treated ani-
mals develop insulin resistance without any
changes in glycemia or weight (35–40 g, with
no signiﬁcant differences between the diverse
treatments applied).
Bisphenol A induces insulin resistance
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Figure 3. Insulin content in β-cells from E2- and BPA-treated mice. (A) Immunoﬂuorescent staining of insulin in cells from mice treated with vehicle, 100 µg/kg/day
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from two mice; *p < 10–5 compared with vehicle. (E) Insulin content of islets obtained from mice treated with vehicle, 100 µg/kg/day E2 (n = 6; *p = 0.014), or
100 µg/kg/day BPA for 4 days (n = 6; **p = 0.04). All error bars indicate SE. Discussion
The results presented in this article demon-
strate a link between estrogenic endocrine dis-
ruptors and insulin resistance. We have shown
that BPA mimics E2 effects on blood glucose
homeostasis through two different pathways.
A nonclassical pathway produces a rapid
increase in plasma insulin and a decrease in
blood glucose. This is unaffected by the anti-
estrogen ICI and is most likely initiated by the
ncmER already described in islet cells (Alonso-
Magdalena et al. 2005; Nadal et al. 2000;
Quesada et al. 2002; Ropero et al. 2002).
Nonetheless, other estrogen and xenoestrogen
actions initiated at the plasma membrane are
mediated via classical ERs (Losel et al. 2003;
Wozniak et al. 2005). The activation of this
alternative pathway occurs at low doses of
both E2 and BPA, becoming significant at
10 µg/kg. When animals were treated with
either the natural hormone or BPA for a
longer period of time, there was an increase in
the pancreatic insulin content. This effect was
completely blocked by ICI, suggesting that a
classical ER is involved. This implies that the
action described here for E2 and BPA can be
extrapolated to other estrogenic EDCs. Any
EDC having an estrogenic effect through clas-
sical ERs can be a candidate to induce insulin
overexpression. This chronic treatment
induced insulin resistance.
Type 2 diabetes mellitus is characterized by
insulin resistance, which results in lower levels
of blood glucose uptake into target tissues.
Consequently, blood glucose levels increase
and more insulin is released, producing hyper-
insulinemia, which manifests early in type 2
diabetes. In addition, several studies have
demonstrated that the hypersecretion of
insulin is a primary defect of type 2 diabetes
and that insulin resistance develops secondarily
to the chronic hyperinsulinemia (Charollais
et al. 2000; DeFronzo 1997; Devedjian et al.
2000; McGurry 1992). Indeed, the persis-
tence of chronic physiologic euglycemic
hyperinsulinemia for 3–5 days can induce
severe insulin resistance in healthy subjects
with normal glucose tolerance (Del Prato
et al. 1994). Furthermore, patients with
insulinoma display a correlation between
hyperinsulinemia and insulin resistance
(Pontiroli et al. 1992; Skrha et al. 1996).
When insulin is overexpressed, a chronic
hyperinsulinemia manifests, as shown in
transgenic mice that overexpressed the insulin
gene (Marban et al. 1989). Remarkably, these
transgenic mice developed insulin resistance.
Here we have shown that 4 days of treatment
with either E2 or BPA induces an increase in
β-cell insulin content; these mice were hyper-
insulinemic and presented altered glucose and
insulin tolerance tests. These alterations may
result from a direct effect of E2 and BPA on
β-cell insulin content, or a compensatory
response resulting from the insulin resistance
noted in these animals, or both.
We have demonstrated that after 4 days of
treatment, isolated islets respond more vigor-
ously to glucose (Figure 5A), likely because
their insulin content is higher (Marban et al.
1989). This phenomenon may be responsible
for the chronic hyperinsulinemia that mani-
fested in the fed state (Figure 5B). In addi-
tion, the altered glucose and insulin tolerance
test results were consistent with the fact that
these mice had developed insulin resistance.
Therefore, our results suggest that the sustained
hyperinsulinemia produced by E2 and BPA
Alonso-Magdalena et al.
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Figure 4. Insulin content in β-cells from E2- and BPA-treated mice with and without treatment with the pure
antiestrogen ICI. (A) Immunoﬂuorescent staining for insulin in mice treated with vehicle, 100 µg/kg/day E2,
or E2 plus 500 µg/kg/day ICI for 4 days. Bar = 50 µm; blue indicates low fluorescence, and red indicates
high fluorescence. (B) Quantification of insulin content using confocal microscopy of β-cells from mice
treated with vehicle, 100 µg/kg/day E2 or BPA, or 100 µg/kg/day E2 or BPA plus 500 µg/kg/day ICI. Each
point represents the mean of at least 2,000 individual cells from four mice; *p <1 0 –10. (C) Insulin content
obtained by radioimmunoassay (n = 6); *p < 0.05, comparing E2 with E2+ICI and BPA with BPA+ICI. All error
bars indicate SE. 
Figure 5. Insulin secretion in vitro and in vivo. (A) Glucose-induced insulin secretion from isolated islets at 3,
7, and 16 mM glucose, from mice treated with vehicle, 100 µg/kg/day E2, or 100 µg/kg/day BPA for 4 days (n
= 4–6 animals per group); *p < 0.005, compared with vehicle. (B) Normalized plasma insulin with respect to
the plasma concentration in mice treated with vehicle, 100 µg/kg/day E2 or 100 µg/kg/day BPA for 4 days (n
= 5–10 mice per group); *p < 0.0075 compared with vehicle. In the E2 group, circulating insulin levels were
1.53 ± 0.25 ng/mL for vehicle-treated mice and 2.58 ± 0.42 ng/mL for E2-treated mice (n = 5; p = 0.038); in the
BPA group, circulating insulin levels were 1.02 ± 0.14 ng/mL for the vehicle-treated mice and 1.56 ± 0.11
ng/mL for those treated with BPA (n = 7; p = 0.005). All error bars indicate SE. Both vehicle groups were com-
bined; the data are normalized with respect to the vehicle value from each group.affects peripheral tissues, producing insulin
resistance, most likely by down-regulation of
insulin receptor number and function.
However, the extent of the insulin resistance
with this treatment is not enough to induce
hyperglycemia in the fasted state.
The assumption described above does not
rule out a direct effect of both E2 and BPA on
peripheral tissue. BPA produces down-regula-
tion of glucose transporters in adipocytes
(Sakurai et al. 2004), an action that may
induce insulin resistance. Moreover, BPA
combined with insulin favors the conversion
of fibroblasts to adipocytes (Masuno et al.
2002), enhancing the risk of obesity, a meta-
bolic disorder that has been related to
endocrine disruptors in the last years (Heindel
2003; Mead 2004). Hence, the direct effect of
BPA on peripheral tissue might also be of
importance to developing insulin resistance.
At present, there is a debate about deter-
mining the safe levels of BPA exposure and
whether there is a need for a new risk assess-
ment (vom Saal and Hughes 2005). The U.S.
EPA considers 50 µg/kg/day as the reference
dose based on a LOAEL of 50 mg/kg/day,
according to studies performed in the 1980s
(vom Saal and Hughes 2005). The ECSCF
(2002) reported a TDI of 10 µg/kg/day. The
results presented here show a rapid nongenomic
effect at a dose of 10 µg/kg/day, five times
lower than the reference dose established by the
U.S. EPA and equal to the TDI reported by the
ECSCF. This dose of BPA results in levels of
parent (unconjugated) BPA in blood of
3–4 nM after 30 min and maintained 24 hr
later (Zalko et al. 2003), below the level
reported in blood from human fetuses at par-
turition (Schonfelder et al. 2002). This low
dose of BPA produces a 2.5-fold increase in
plasma insulin and a 20% decrease in blood
glucose levels, 30 min after its application.
Remarkably, a low dose of 10 µg/kg/day was
able to slightly change insulin content as well.
A higher dose of 100 µg/kg/day dramatically
increased pancreatic insulin content after only
4 days of exposure. Moreover, this treatment,
delivering BPA either via injection or through
oral intake, induced insulin resistance. This
dose is only twice the reference dose recom-
mended by the U.S. EPA and 10 times higher
than the TDI recommended by the ECSCF.
The present study demonstrates a connec-
tion between BPA and insulin resistance at
doses much lower than the LOAEL used up
to now (50 mg/kg/day), and therefore it is
strong evidence supporting a review of the
risk assessment concerning BPA.
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